Literature DB >> 19332199

Implantable cardioverter-defibrillator deactivation at the end of life: a physician survey.

Amy S Kelley1, M Carrington Reid, David H Miller, Joseph J Fins, Mark S Lachs.   

Abstract

BACKGROUND: Among older adults, implantable cardioverter-defibrillator (ICD) use is increasing. ICD shocks can occur at end of life (EOL) and cause substantial distress, warranting consideration of ICD deactivation discussions. This nationwide physician survey sought to (1) determine if physicians discuss ICD deactivation at the EOL, (2) identify predictors of those discussions, and (3) ascertain physicians' knowledge/attitudes about ICD use.
METHODS: We surveyed 4,876 physicians stratified by specialty (cardiologists, electrophysiologists, general internists, and geriatricians). The mailed survey presented 5 vignettes (eg, end-stage chronic obstructive pulmonary disease, advanced dementia) wherein ICD deactivation might be considered and 17 Likert-scaled items.
RESULTS: Five hundred fifty-eight (12%) physicians returned surveys. Respondents were largely men (77%) and white (69%). Most physicians (56%-83%) said they would initiate deactivation discussions in all 5 vignettes, whereas significantly more (82%-94%) would discuss advance directives and do not resuscitate status. In logistic regression analyses, a history of prior deactivation discussions was an independent predictor of willingness to discuss deactivation (adjusted OR range, 2.8-8.8) in 4 of the 5 vignettes. General internists and geriatricians were less likely than electrophysiologists to agree that ICD shocks are painful and to distinguish between the ICD's pacing and defibrillator functions. Finally, most physicians believed that informed consent for ICD implantation should include information about deactivation (77%) and endorsed the need for expert guidance in this area (58%).
CONCLUSIONS: Most physicians would discuss ICD deactivation at EOL. The strongest predictor of this was a history of prior discussions. Knowledge about ICDs varies by specialty, and most expressed a desire for more expert guidance about ICD management at EOL.

Entities:  

Mesh:

Year:  2009        PMID: 19332199     DOI: 10.1016/j.ahj.2008.12.011

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  26 in total

1.  Determinants of treatment intensity for patients with serious illness: a new conceptual framework.

Authors:  Amy S Kelley; R Sean Morrison; Neil S Wenger; Susan L Ettner; Catherine A Sarkisian
Journal:  J Palliat Med       Date:  2010-07       Impact factor: 2.947

2.  Evaluation of a Novel Educational Intervention to Improve Conversations About Implantable Cardioverter-Defibrillators Management in Patients with Advanced Heart Failure.

Authors:  Ian B Kwok; Harriet Mather; Karen McKendrick; Laura Gelfman; Mathew D Hutchinson; Rachel J Lampert; Hannah I Lipman; Daniel D Matlock; Keith M Swetz; Jill Kalman; Sean Pinney; R Sean Morrison; Nathan E Goldstein
Journal:  J Palliat Med       Date:  2020-06-29       Impact factor: 2.947

3.  [Implantable cardioverter-defibrillator at the end of life].

Authors:  D Pfeiffer; A Hagendorff; C Kühne; S Reinhardt; N Klein
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2015-05-22

Review 4.  Effective communication and ethical consent in decisions related to ICDs.

Authors:  Alexander M Clark; Tiny Jaarsma; Patricia Strachan; Patricia M Davidson; Megan Jerke; James M Beattie; Amanda S Duncan; Chantal F Ski; David R Thompson
Journal:  Nat Rev Cardiol       Date:  2011-07-26       Impact factor: 32.419

Review 5.  Implantable Cardioverter-Defibrillator Use in Older Adults: Proceedings of a Hartford Change AGEnts Symposium.

Authors:  Daniel B Kramer; Daniel D Matlock; Alfred E Buxton; Nathan E Goldstein; Carol Goodwin; Ariel R Green; James N Kirkpatrick; Christopher Knoepke; Rachel Lampert; Paul S Mueller; Matthew R Reynolds; John A Spertus; Lynne W Stevenson; Susan L Mitchell
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-06-02

6.  Communicating with cancer patients: what areas do physician assistants find most challenging?

Authors:  Patricia A Parker; Alicia C Ross; Maura N Polansky; J Lynn Palmer; M Alma Rodriguez; Walter F Baile
Journal:  J Cancer Educ       Date:  2010-04-10       Impact factor: 2.037

Review 7.  Ethical challenges of deactivation of cardiac devices in advanced heart failure.

Authors:  Hassan Chamsi-Pasha; Mohammed A Chamsi-Pasha; Mohammed Ali Albar
Journal:  Curr Heart Fail Rep       Date:  2014-06

Review 8.  The deactivation of implantable cardioverter-defibrillators: medical, ethical, practical, and legal considerations.

Authors:  Jörg Carlsson; Norbert W Paul; Matthias Dann; Jörg Neuzner; Dietrich Pfeiffer
Journal:  Dtsch Arztebl Int       Date:  2012-08-20       Impact factor: 5.594

Review 9.  Deactivation of pacemakers and implantable cardioverter-defibrillators.

Authors:  Daniel B Kramer; Susan L Mitchell; Dan W Brock
Journal:  Prog Cardiovasc Dis       Date:  2012 Nov-Dec       Impact factor: 8.194

Review 10.  Life-saving devices reach the end of life with heart failure.

Authors:  Daniel D Matlock; Lynne Warner Stevenson
Journal:  Prog Cardiovasc Dis       Date:  2012 Nov-Dec       Impact factor: 8.194

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.